WO2006104403A1 - Skin treatment compositions - Google Patents
Skin treatment compositions Download PDFInfo
- Publication number
- WO2006104403A1 WO2006104403A1 PCT/NZ2006/000060 NZ2006000060W WO2006104403A1 WO 2006104403 A1 WO2006104403 A1 WO 2006104403A1 NZ 2006000060 W NZ2006000060 W NZ 2006000060W WO 2006104403 A1 WO2006104403 A1 WO 2006104403A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- luteus
- corynebacterium
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/265—Micrococcus
Definitions
- This invention relates to Micrococcus luteus containing compositions useful for controlling skin disorders, more particularly, the invention relates to compositions intended for topical application to prevent or treat skin disorders in which bacteria are a causative component, for example, body odour, skin infections and acne.
- a new strain of Micrococcus luteus useful in these compositions is also provided.
- Skin disorders including malodour are often attributable to the action of microorganisms on the skin.
- a range of products including proteins, lipids, salts and acids are secreted by glands in the skin. While the fresh secretions are often odourless, microbial decomposition of the secreted products can result in offensive odours being produced.
- Control of body odour is most commonly addressed through the use of antiperspirants or deodorants.
- Deodorants are generally designed to mask offensive odours or to prevent production of same.
- Antiperspirants are intended to prevent or control perspiration on the skin, and may also function as a deodorant.
- deodorant or antiperspirant products make use of aluminium salts or zinc salts. These compounds can cause irritation, itching and burning on individuals with sensitive skin.
- aluminium salts or zinc salts can cause irritation, itching and burning on individuals with sensitive skin.
- Skin infections may be caused by a range of bacteria including Staphylococcus species, (particularly S.
- the present invention is broadly directed to compositions and methods for controlling skin disorders using Micrococcus luteus strains, or at least provides the public with a useful choice.
- the invention provides a biologically pure culture of M. luteus strain Q24 on deposit at Deutsche Sammlung von Mikroorganisms Und Zellkulturen GmbH, Braunschweig, Germany, under accession number DSM 17172, or a culture having the identifying characteristics thereof.
- the invention also provides a composition
- a composition comprising M. luteus strain Q24 or a culture having the identifying characteristics thereof together with a diluent, carrier and/or excipient.
- the invention provides a composition comprising a strain of M. luteus effective to at least inhibit one or more bacteria selected from the group consisting of Staphylococcus species, Propionibacterhim species, Corynebacteriwn species, and Sti-eptococcus species, and aerobic diphtheroids.
- the invention provides a composition comprising a strain of M. lutens effective to at least inhibit growth of one or more bacteria selected from the group consisting of Propionibacterium acnes.
- Staphylococcus aureus Staphylococcus saprophytics, Staphylococcus simulans, Corynebacterium diphtheriae, Corynebacterium ulcer ans, Corynebacterium minutissium, Corynebacterium tenuis, Streptococcus pyogenes Streptococcus agalactiae, and Streptococcus dysgalactiae together with a diluent, carrier and/or excipient.
- the M. luteus strain inhibits at least four of the group of bacteria above, preferably eight and more preferably all eleven.. These bacteria are generally recognised as skin bacteria.
- the Staphylococcus aureus is methicillin resistant.
- the M. luteus is strain Q24.
- composition is formulated for topical administration.
- Topically administrable forms include powders, emulsions, unguents, pastes, oils, gels, lotions, creams, suspensions, nasal sprays, roll ons, sticks or aerosol sprays, semi-solid and solid formulations.
- the invention provides a method for at least inhibiting the growth of bacteria sensitive to M. luteus, the method comprising contacting the sensitive bacteria with an inhibitory effective amount of an M. luteus strain or a composition of the invention.
- the invention also provides a prophylactic or therapeutic method of treatment for skin disorders in an individual in need thereof.
- the method comprising administering to said individual an M. luteus strain, or a composition of the invention in an amount effective to at least inhibit growth of one or more bacteria causing the skin disorder, or in an amount to allow effective colonisation of the skin of the individual by the M. luteus.
- the invention provides a method of controlling the incidence and/or severity of a skin disorder, the method comprising introducing to the skin of the individual an amount of M. luteus, or composition of the invention, effective to control the incidence or severity of said skin disorder.
- Skin disorders amenable to treatment according to the present invention include skin infections, such as impetigo, erysiphelas, folliculitis, acne, boils, carbuncles, cellulitis, pitted keratolysis, intertrigo, trichomycosis, mastitis, toe infections such as tinea, and body odour.
- skin infections such as impetigo, erysiphelas, folliculitis, acne, boils, carbuncles, cellulitis, pitted keratolysis, intertrigo, trichomycosis, mastitis, toe infections such as tinea, and body odour.
- Bacteria responsible for skin disorders that may be controlled according to the present invention include Propionibacterinm species, including Propionibacterium acnes, Streptococci species including Streptococcus pyogenes. Streptococcus agalactiae, and Streptococcus dysgalactiae, Staphylococcus species including Staphylococcus simulans, Staphylococcus saprophytics and Staphylococcus aureus, Corynebacte ⁇ um species including Corynebacterium diphtheriae, Corymb acter him ulcerans, Corynebacterium tenuis and Corynebacterium minutissimum. Included in this group are aerobic diphtheroids. This is a group of Corynebacterium commonly regarded as responsible at least in part for body odour.
- the existing population of skin microflora is reduced prior to, or simultaneously with treatment using a method of the invention.
- the invention also relates to the use of M. luteus, or compositions of the invention in the methods discussed above. Particularly, to the use of M. luteus in the preparation of medicament for use in treating skin disorders as above including body odour, skin infections (particularly acne), and toe infections.
- M. luteus strain Q24 M. luteus strain was deposited by the assignee under the terms of the Budapest Treaty with Deutsche Sammlung von Mikroorganismen Und Zellkulturen GmbH, Braunschweig, Germany on 10 March 2005, and assigned Accession No. 17172.
- M. luteus is a gram positive spherical saprophytic bacterium.
- the organism is a natural inhabitant of the human skin, and can occasionally be found in the mucous membranes. It is considered non-pathogenic and can be spread through direct contact. It is common in the environment but survives for only a limited time in soil or water.
- the species is a non- spore forming, obligate aerobe that produces creamy white to yellow insoluble pigments.
- a full morphological description is provided in the accompanying examples.
- M. luteus strains having the identifying characteristics of Q24 as set forth in the examples. These strains may be mutants which are natural products or artificially produced by manipulations such as chemical or UV mutagenesis, or genetic modification.
- M. luteus Q24 and other M. luteus strains having the identifying characteristics thereof are useful for at least inhibiting the growth of bacteria such as Propionibacterhim species including Propionibacterium acnes; Staphylococcus species including Staphylococcus aureus (all of 24 tested strains were sensitive including 20 that were methicillin resistant), Staphylococcus saprophyticus; and Staphylococcus simulans; Coiynebacterium species including, Corynebacterhim diphtheriae, Corynebacterium ulcerans, Corynebacte ⁇ um tenuis, Corynebacterium minutissimum * Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus dysgalactiae. Included in this group are aerobic diphtheroids. This is a group of Corynebacterium commonly regarded as being at least in part responsible for body odour.
- M. luteus serves as an effector strain to replace bacteria involved in causing skin disorders.
- An effector strain is one which can compete successfully with the disorder-causing organism either via competitive action (eg for attachment sites; or inhibition by other metabolism-associated by-products; or a combination thereof).
- the M. luteus of the invention exhibit broad spectrum antibacterial activity.
- the M, httens are therefore useful as an antibacterial agent per se as well as therapeutically.
- the M. luteus are also useful as an antifungal agent per se.
- therapeutic includes prophylactic treatment.
- Therapeutic uses include the treatment or prevention of bacterial infections, particularly Staphylococcus, Streptococcus, Propionibacterium, and
- the Micrococcus luteus of the invention are particularly suitable for use against the bacteria S. aureus, P. acnes, Corynebacterium minutissimum and S. pyogenes Conditions amenable to treatment with the strains or compositions of the invention include skin infections (including acne), toe infections, and body odour.
- 'intertrigo is polymicrobial disorder like many skin diseases the infection often results from infection by normal commonsal organisms of the skin. Resident and transient bacteria most usually include Staphylococcus species, Streptococcus species Propionihacteria species, aerobic diphtheroids and some Candida species.
- Tinea is a polymicrobial infection usually involving dermatophyte fungi such as Trichophyton, Epidennophyton and Microsporum. Secondary bacterial infections are also commonly implicated in Tinea's. Causative organisms include Staphylococcus species, Streptococcus species, Pseudomonas, and Corynebacterium minutissimum. (See Gupta AK et., Dermatology Clinics vol 21; p431-62, 2003 Treatments of Tinea pedis).
- Mastitis is also a polymicrobial infection.
- Key causative organisms include Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae, Escherischia coli, and Klebsiella pneumoniae.
- skin disorders as used herein is therefore to be broadly understood as encompassing bacterial diseases of the skin, and mucosa, caused at least in part by one or more bacteria of the genera Staphylococcus, Streptococcus, Corynebacterium, and Propionibacterium or by bacteria of the group aerobic diphtheroids.
- Topical therapeutic formulations are particularly useful.
- topical refers to compositions suitable for application to skin or mucosal surfaces of the body. Mucosal surfaces include the nasal cavity.
- a “therapeutic formulation” is a formulation appropriate for administration of an M. luteus strain to an individual in need of same, particularly an individual susceptible to skin disorders.
- therapeutic formulations of the invention are composed of an M. luteus strain of the invention and an acceptable carrier, diluent and/or excipient.
- an "acceptable carrier, diluent and/or excipient” means a vehicle for delivery of a M luteus strain of the invention, to the individual, in which the vehicle is compatible with bacterial cell viability.
- Acceptable carriers suitable for use in the administration of viable M. luteus strains of the invention are well known to those skilled in the art. Suitable carriers are generally inert and can be either solid or liquid.
- the carrier is a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers suitable for use with the M. luteus strains herein include, but are not limited to buffered saline solutions (e.g., phosphate-buffered saline), pharmaceutically acceptable culture media (e.g. TSB), or other solutions which maintain the viability of the bacterium. Additionally, such pharmaceutically acceptable carriers may be non-aqueous solutions, suspensions, and emulsions.
- Suitable solid carriers suitable for administration of viable or lyophilized bacteria are well known in the art (see, for example, Remington's Pharmaceutical Sciences, 18th ed., Gennaro, ed., 1990, Mack Publishing Co., Easton, Pa., incorporated herein by reference.
- Suitable solid carriers known in the art include, for example, magnesium carbonate; magnesium stearate; celluloses; talc; sugars such as fructose, sucrose, dextrose, trehalose, mannitol, lactose; starches; and flours; but are not limited thereto.
- Oleaginous carriers suitable for use in the compositions of the invention include glycerol, mineral oils, essential oils, fats, fatty acids and esters thereof, glycerides, propylene glycol, lanolin, and derivatives, lecithin and derivatives, white petrolatum petroleum jelly, emulsions formed from oil(s) and water, and may be mixed to form liquids, gels, creams, emulsions, pastes, suspensions, semi-solids, solids or aerosols amongst others. Detergents and surfactants such as Tween 80 may also be added.
- oils and fats such as cocco butter, shea butter, grapeseed oil and chamomile oil.
- Phase formulations including aqueous and oil phases with the hi luteus or composition of the invention in an oil phase are also feasible.
- the phase formulation is a two phase formulation with one oil and one aqueous phase.
- compositions may also include excipients such as known art preservatives; thickening agents; opacifiers; binders; antioxidants; emulsifiers; buffers; colourings; anti-caking agents; fillers; mineral salts; essential oils; botanical extracts; and fragrances as appropriate.
- excipients for example carbohydrates such as xylitol, lactose and maltose or the like, and/or proteins such as casein
- Nutrients for example carbohydrates such as xylitol, lactose and maltose or the like, and/or proteins such as casein
- Emollients to improve cosmetic properties and facilitate application of the composition can also be included.
- emollients are silicones such as DC246 and DC556 (Dow Corning, USA), fatty acid esters such as Esto/RTM1517 (Unichem) but are not limited thereto.
- the carriers and excipients selected must not significantly affect the antibacterial, activity of the M. luteus.
- a currently preferred composition includes a salt such as rock salt or sodium chloride but not limited thereto. Because many bacteria and fungi involved in skin disorders are salt sensitive, the inclusion of salt in the composition also helps to reduce the bacterial populations on the skin, nails or mucosa. This allows for more effective colonisation by the M. luteus strain.
- a salt such as rock salt or sodium chloride but not limited thereto. Because many bacteria and fungi involved in skin disorders are salt sensitive, the inclusion of salt in the composition also helps to reduce the bacterial populations on the skin, nails or mucosa. This allows for more effective colonisation by the M. luteus strain.
- Salt is most usually included at a concentration of 1 to 10%, preferably 3 to 7%, and more preferably 5% by weight of the composition
- the M. luteus strains of the invention can be formulated in any of a variety of compositions suitable for topical administration, including mucosal administration.
- the M. luteiis strains can be formulated for administration as a lyophil or cell paste prepared from a M. luteiis culture, or can be directly administered to the site of the skin disorder.
- the strain can also be administered in the form of a cream, gel, emulsion, oil, paste, lotion, wash, suspension, spray (including nasal spray), powder, stick, roll-on or aerosol, solid or semi-solid but the forms are not limited thereto.
- a deodorant stick may be produced by melting cocco and shea butter, and mixing in freeze-dried M. luteiis powder. The mixture is then poured into a deodorant stick container and cooled until solid.
- the M. luteus can be a component of a face wash, soap, lotion, cream unguent gel, emulsion or the like.
- the M, luteus may conveniently form part of an existing skin treatment regime product. For example, a face wash, cleanser or moisturiser.
- the M. luteus can be formulated as a powder, oil, wash, cream, soap, achet lotion, or spray (including nasal sprays).
- Formulations such as bath oils, and soaps are useful for treating skin infections identified herein.
- formulations may also be produced for other methods of administration including transdermal administrable fo ⁇ nulations, but not limited thereto.
- the M. luteus, compositions and formulations of the invention may also be topically administered indirectly, such as in material for contacting the skin or mucosa.
- material for contacting the skin or mucosa for example, in nappies, wet wipes, sanitary pads, clothing articles and the like.
- the M, luteus can be applied to the material by known art techniques such as spraying and drying.
- the formulations and compositions of the invention may further comprise one or more secondary antibacterial agents.
- These secondary agents may, for example, be antibiotics, or other antibacterial agents or antibacterial producing microorganisms.
- Useful antibacterials include bacteriocin-like inhibiting substances (BLIS) such as nisin, epidermin and salivaricins A, A 1 , A 2 and B for example.
- BLIS bacteriocin-like inhibiting substances
- Other antibacterial compounds such as potassium alum may also be included. Any antibacterial must also be compatible with M. lutens viability.
- the secondary antibacterial may be included at a concentration of 1 to 20%, commonly 3 to 15%, preferably 4 to 10%, more preferably 1 to 9%, by weight of the composition and even more preferably 7.5%.
- the M. luteus comprise about 0.01% to about 99% by weight of the final composition, commonly 0.05 to 50%, preferably 0.075 to 20%, more preferably 0.1 to 10% by weight of the composition or formulation suitable for topical administration.
- M. luteus strains of the invention can be administered to any susceptible individual.
- the term "individual” as used herein includes humans, horses, dogs, cats, pigs, sheep, cattle, goats but is not limited thereto. Preferably, the individual is a human.
- the M. luteus strains can be administered to the individual at any age, e.g. childhood, adolescence, or adulthood.
- the M. luteus of the invention can be administered in a variety of ways. For example, in the form of compositions or formulations discussed above, or as suspensions, sustained release formulae or lyophil powders.
- the M. luteus strains can also be administered by direct application of a lyophil, culture, or cell paste to the affected skin, nail or mucosal surface of the individual. Any mode of administration is suitable as long as the therapeutic formulation is applied to the skin, or mucosa.
- the amount of M. luteus administered to the individual will be an amount effective for replacement of skin disorder causing bacteria or fungi on the skin of the individual.
- An amount effective for replacement of skin disorder causing bacteria on the skin of the individual means an amount effective for skin colonisation by the M. luteus strain, and significant reduction of the resident skin disorder-causing bacteria (e.g. by competition between the bacteria for attachment sites, nutrients and/or by antibacterial action).
- unit dose when used in reference to a therapeutic formulation of the present invention refers to physically discrete units suitable as unitary dosage for the individual, each unit containing a predetermined quantity of active material (viable M l ⁇ teus) calculated to produce the desired therapeutic effect in association with the required diluent, carrier, or excipient.
- Specific dosages can vary widely according to various individual variables including size, weight, age, disease severity (e.g. the tenacity and/or number of skin disorder causing resident bacteria, or fungi) and responsiveness to therapy (e.g. the susceptibility of the individual's skin to colonisation).
- Methods for determining the appropriate route of administration and dosage may be determined by the consumer as they deem appropriate, or on a case-by-case basis by an attending doctor, pharmacist, or other clinician. Such determinations are routine to one of ordinary skill in the art (see for example, Remington's Pharmaceutical Sciences, 8th ed., Gennaro, ed., Mack Publishing Company, Easton, Pa., 1990).
- the number of M. luteus administered to the individual will range from about 10 2 to 10 15 bacteria, preferably from about 10 3 to 10 10 bacteria, more preferably from about 10 4 to 10 8 bacteria, normally about 10 6 to 10 7 colony forming units (CFU) per dose.
- CFU colony forming units
- M. luteus strains can be administered to achieve colonisation and replacement of the resident, skin disorder causing bacteria or fungi.
- the M. luteus strains may need to be administered to the patient once only or repeatedly. Repeat treatments may be once a month, once a week, once a day, two or three times a day, or as may otherwise be required. Conveniently, the administration may be effected as part of the patient's routine grooming.
- the M. luteus or composition of the invention should be applied to affected body parts such as axilla, groin, feet and skin folds. Most conveniently application is made after showering.
- M. luteus may be in the form of a face wash, cleanser, moisturiser or similar used in routine grooming, or may be applied in the form of a cream or the like.
- Tinea can affect a variety of surfaces and body parts including skin folds. Tinea commonly occurs on the feet (Tinea pedis) ', groin (Tinea cruris), body (Tinea corporis), toenails (Tinea unguium), or scalp (Tinea capitis) As discussed above Tinea is a polymicrobial skin infection. Athlete's foot is usefully treated by direct application of the organism or composition of the invention to the affected area. Oils and powders are particularly useful for this purpose.
- M. luteus Many infections also arise at sites of trauma, for example scratches, grazes and cuts. These trauma sites allow colonisation by normal commensal organisms of the skin.
- Common skin infectious agents treatable using M. luteus or compositions of the invention are listed above and include S. pyogenes, S. aureus, P. acnes, and aerobic coryneforms.
- Staphylococcus aureus including methicillin resistant strains
- Nasal sprays of the invention can be used to treat or eliminate the carriage of S. aureus and similar pathogens.
- Therapeutic treatment of health and food workers to eliminate resistant S. aureus from skin, and nasal passages is desirable to prevent spread of infection.
- Mastitis involves mammary gland infection by skin bacteria. Prevention or treatment of mastitis is usefully achieved by teat or nipple washes.
- the treatment method of the invention includes a preliminary step of pre-treating the individual to at least reduce the normal microflora present on the skin surface.
- This pre-treatment may be as simple as carrying out normal grooming procedures such as washing with soap and water, or using a salt scrub, showering, skin cleansing, and usual treatments for acne.
- M. luteus of the invention is then administered to the depopulated environment to repopulate same.
- Successful colonisation of the individual's skin by the M. luteus strain can be established by culturing the bacteria of the individual's skin, and identifying the M. luteus using methods well known in the art for bacterial strain identification such as 16 sRNA identification.
- the methods and uses of the invention may further comprise the use of one or more secondary antibacterial agents, as discussed above.
- the M. luteus and compositions of the invention may also be used in conjunction with existing treatment products such as acne treatment products, deodorants and antiperspirants, cleansers, toners and moisturisers but not limited thereto.
- M. luteus strain Q24 was isolated from the skin of a healthy adult male subject and cultured into blood agar plates. The plates were incubated at 35-37 0 C, 5% CO 2 in air. Comparison of the amplified 16S rRNA variable gene region with data bases established the organism to be Micrococcus luteus. Its appearance on blood agar is consistent with Micrococcus luteus. Individual colonies are convex, circular, entire, smooth and become creamy-yellow-pigmented on prolonged incubation. Gram-stained appearance was of Gram-positive cocci (1 micrometre diameter) in irregular clumps.
- the biochemical characteristics were determined using the ID32 Staph and API 50 CH kits (bioMerieux).
- M. hiteiis strain Q24 The ability of M. hiteiis strain Q24 to inhibit bacteria associated with skin disorders was assessed in a deferred antagonism test against nine standard indicator strains.
- the P-typing test involves first growing the test strain on blood agar as a diametric streak culture. After removing this growth, the agar surface is sterilized with chloroform vapour, aired and the 9 standard indicator bacteria (set out in table 1) are cross-streaked across the line of the original test strain inoculum. Following incubation, interference with growth of the indicators in the vicinity of the original producer streak is taken as indicative of inhibitory activity. Relative zone size is indicated qualitatively on a scale of +-(reduction in growth on indicator in a zone approximately the width of the original producer streak) to +++ (Clear inhibition zone three times the width of the original producer streak).
- Lactococcus lactis (subspecies lactis) (Group-N) strain T-21 +++
- the table 1 shows a P-type 777 pattern signifying inhibitory activity against all nine indicators. Activity was particularly strong against a Micrococcus strain, S. pyogenes, L. lactis and S. equisimilis.
- Micrococcus luteus Q24 Producer strain
- a saline suspension of M. luteus Q24 with a concentration of approximately 1 x 10 6 CFU per dose was inoculated by swabbing one axilla of each of several test subjects after showering.
- the inoculated strain has been shown to persist for at least 24 hours. Subjective comparison of the body odour of the two axilla by the subjects and by "blinded" assessors found the Q24 inoculated axilla to be relatively odour free when compared with the control axilla.
- the deodorant stick was prepared by melting cocco and shea butter at 40°C. M. hit ens Q24 freeze-dried powder was mixed with the molten butter and poured into a deodorant 5 stick container. The mixture was cooled at 4 0 C until solid.
- the Q24 cell count for the deodorant stick was 5 x 10 6 cfu/g
- the subject had a shower as per usual and then applied the Q24 deodorant stick to the left 0 axilla.
- the right axilla was used as a control.
- a cotton swab was soaked in sterile saline/1% Tween 80 and used to swab the axilla region.
- the swab sample was resuspended in 1 ml saline/ 1% Tween 80.
- Body odour was self assessed by smelling their own axilla (0 - no odour, 1 slight odour, 3- strong odour, 5- very strong odour). 0 Table 3. Effect of M. Intern Q24 on staphylococcus and corynebacterial axilla populations.
- the M. luteus Q24 had a slight effect on the staphylococcus cell counts while there was a 0.6 log reduction in the corynebacterial cell counts at 7 hours (Table 3).
- the odour score on the control axilla increased over 24 hours while the treated axilla only slightly increased (Table 4).
- the oil formulation was prepared by mixing M. luteus freeze-dried powder with the oils to produce a suspension formulation.
- the Q24 cell count for the deodorant stick was 1.2 x 10 7 cfu/g.
- the formulation was applied to the infected area of five subjects with athlete's foot daily for three days. Within 10 minutes the itchy symptoms had disappeared. After three days no further application was required due to cessation of the signs of infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006229563A AU2006229563B2 (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
ES06733149T ES2430377T3 (en) | 2005-03-29 | 2006-03-29 | Compositions of skin treatment |
CN2006800107252A CN101163788B (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
CA2602108A CA2602108C (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
DK06733149.6T DK1863899T3 (en) | 2005-03-29 | 2006-03-29 | skin treatment |
JP2008503984A JP5313659B2 (en) | 2005-03-29 | 2006-03-29 | Skin treatment composition |
PL06733149T PL1863899T3 (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
EP06733149.6A EP1863899B1 (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
US12/710,542 US8283136B2 (en) | 2005-03-29 | 2010-02-23 | Skin treatment compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ539076 | 2005-03-29 | ||
NZ539076A NZ539076A (en) | 2005-03-29 | 2005-03-29 | Skin treatment compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006104403A1 true WO2006104403A1 (en) | 2006-10-05 |
Family
ID=37053612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ2006/000060 WO2006104403A1 (en) | 2005-03-29 | 2006-03-29 | Skin treatment compositions |
Country Status (11)
Country | Link |
---|---|
US (1) | US8283136B2 (en) |
EP (1) | EP1863899B1 (en) |
JP (1) | JP5313659B2 (en) |
CN (1) | CN101163788B (en) |
AU (1) | AU2006229563B2 (en) |
CA (1) | CA2602108C (en) |
DK (1) | DK1863899T3 (en) |
ES (1) | ES2430377T3 (en) |
NZ (1) | NZ539076A (en) |
PL (1) | PL1863899T3 (en) |
WO (1) | WO2006104403A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3666341A1 (en) | 2018-12-14 | 2020-06-17 | DWI - Leibniz-Institut für Interaktive Materialien e.V. | Topical formulation in form of a patch, a bandage or a plaster comprising probiotic bacteria, and use thereof in a method for treating or preventing skin disorders |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2022185238A1 (en) * | 2021-03-04 | 2022-09-09 | Blis Technologies Limited | Topical composition and use thereof |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
WO2024047589A1 (en) * | 2022-09-02 | 2024-03-07 | Blis Technologies Limited | Topical compositions of micrococcus luteus q24 and use thereof |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3360560A1 (en) * | 2012-03-17 | 2018-08-15 | The Regents of the University of California | Composition for treating acne |
US9913800B2 (en) | 2015-04-28 | 2018-03-13 | The Procter & Gamble Company | Compositions and methods for improving skin health |
AR106611A1 (en) * | 2015-11-05 | 2018-01-31 | Natura Cosmeticos Sa | MUCINE TOPICAL DEODORANTS AND ANTITRANSPIRANTS |
US9889165B2 (en) | 2016-04-21 | 2018-02-13 | Naked Biome, Inc. | Compositions and methods for treatment of skin disorders |
BE1024425B9 (en) * | 2016-06-21 | 2018-03-26 | Yun NV | DERMATOLOGICAL PREPARATIONS FOR MAINTENANCE AND / OR REPAIR OF HEALTHY SKIN MICROBIOTA |
WO2018073278A1 (en) * | 2016-10-18 | 2018-04-26 | Universite Paris Descartes | Cosmetic composition for preventing and/or treating body odor |
EP3664819A1 (en) * | 2017-08-08 | 2020-06-17 | Université de Versailles Saint Quentin en Yvelines | Pharmaceutical composition and methods for the prevention of staphylococcus aureus using artificial bacterial colonization |
WO2019168327A1 (en) * | 2018-02-28 | 2019-09-06 | 주식회사 엠디헬스케어 | Nanovesicles derived from micrococcus bacteria and use thereof |
KR102118197B1 (en) | 2018-02-28 | 2020-06-02 | 주식회사 엠디헬스케어 | Nanovesicles derived from Micrococcus bacteria and Use thereof |
CN110680836B (en) * | 2018-06-19 | 2021-04-02 | 景岳生物科技(中国)有限公司 | Application of lactobacillus paracasei strain GMNL-653 in preparation of bromhidrosis improving composition |
US20220184153A1 (en) * | 2019-03-25 | 2022-06-16 | The State of Israel, Ministry of Agriculture&Rural Development, Agricltural Research Oganization(ARO | Method of treating bovine mastitis |
FR3097560B1 (en) * | 2019-06-24 | 2021-06-25 | Oreal | Method for diagnosing chronic exposure to pollution |
KR102273233B1 (en) * | 2020-05-08 | 2021-07-06 | 코스맥스 주식회사 | Micrococcus luteus strain and skin condition improving uses of thereof |
TW202408552A (en) * | 2022-05-16 | 2024-03-01 | 日商瑪路弘股份有限公司 | Composition for treating ringworm |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995030751A1 (en) * | 1994-05-07 | 1995-11-16 | Ciba-Geigy Ag | Lanthionine-containing antimicrobial compound |
WO1997048408A2 (en) * | 1996-06-20 | 1997-12-24 | Novartis Ag | Method for the prevention and treatment of mastitis |
DE10027928A1 (en) * | 2000-06-06 | 2002-01-03 | Peter Michael Siemens | Use of fatty acid oligoethylene glycol ester derivatives for treating bacterial infections and as bactericides, preservatives and disinfectants |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4719109A (en) * | 1987-03-27 | 1988-01-12 | E. R. Squibb & Sons, Inc. | EM5596--an antibiotic |
DE4231544C1 (en) * | 1992-09-21 | 1994-02-03 | Richter Chem Lab | Cosmetic agents |
DE4231543C2 (en) * | 1992-09-21 | 1995-06-29 | Richter Chem Lab | Medicinal products with anti-inflammatory action |
NL1000681C2 (en) * | 1995-06-28 | 1996-12-31 | Suiker Unie | Deo composition. |
KR100211674B1 (en) * | 1997-02-25 | 1999-08-02 | 윤종용 | Novel microorganism which is resistant to hydrogen peroxide |
DE20214753U1 (en) * | 2002-09-24 | 2002-12-12 | Hando Handels Ges. M.B.H., Graz | Pharmaceutical composition for the treatment and / or prevention of light eruption |
US20080193393A1 (en) * | 2004-09-24 | 2008-08-14 | Lipo Chemicals Inc. | Delivery System for Topically Applied Compounds |
KR20080064139A (en) * | 2005-11-01 | 2008-07-08 | 다우 코닝 코포레이션 | Silicone vesicles containing actives |
-
2005
- 2005-03-29 NZ NZ539076A patent/NZ539076A/en unknown
-
2006
- 2006-03-29 ES ES06733149T patent/ES2430377T3/en active Active
- 2006-03-29 DK DK06733149.6T patent/DK1863899T3/en active
- 2006-03-29 CN CN2006800107252A patent/CN101163788B/en active Active
- 2006-03-29 CA CA2602108A patent/CA2602108C/en active Active
- 2006-03-29 JP JP2008503984A patent/JP5313659B2/en active Active
- 2006-03-29 WO PCT/NZ2006/000060 patent/WO2006104403A1/en active Application Filing
- 2006-03-29 AU AU2006229563A patent/AU2006229563B2/en active Active
- 2006-03-29 EP EP06733149.6A patent/EP1863899B1/en active Active
- 2006-03-29 PL PL06733149T patent/PL1863899T3/en unknown
-
2010
- 2010-02-23 US US12/710,542 patent/US8283136B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995030751A1 (en) * | 1994-05-07 | 1995-11-16 | Ciba-Geigy Ag | Lanthionine-containing antimicrobial compound |
WO1997048408A2 (en) * | 1996-06-20 | 1997-12-24 | Novartis Ag | Method for the prevention and treatment of mastitis |
DE10027928A1 (en) * | 2000-06-06 | 2002-01-03 | Peter Michael Siemens | Use of fatty acid oligoethylene glycol ester derivatives for treating bacterial infections and as bactericides, preservatives and disinfectants |
Non-Patent Citations (9)
Title |
---|
"Antibiotic Resistance", 1 September 2000, HUMANA PRESS |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO. |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY |
BIBEL D.J. ET AL.: "Inhibition of diptheroid esterase by Micrococcus luteus", CANADIAN JOURNAL OF MICROBIOLOGY, vol. 23, no. 10, October 1977 (1977-10-01), pages 1319 - 1326, XP009125520 * |
CLEVELAND R.F. ET AL.: "Inhibition of Bacterial Wall Lysins by Lipoteichoic Acids and Related Compounds", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 67, no. 3, 1975, pages 1128 - 1135, XP024772843 * |
GRAVES ET AL., JOURNAL OF CLINICAL EPIDEMIOLOGY, vol. 43, 1990, pages 35 - 44 |
GUPTA AK: "Dermatology Clinics", TREATMENTS OF TINEA PEDIS, vol. 21, 2003, pages 431 - 62 |
P.D DABRE., JOURNAL OF APPLIED TOXICOLOGY, vol. 23, no. 2, 2003, pages 89 - 95 |
See also references of EP1863899A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US10874700B2 (en) | 2016-03-31 | 2020-12-29 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11633451B2 (en) | 2016-03-31 | 2023-04-25 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US11998575B2 (en) | 2016-03-31 | 2024-06-04 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
EP3666341A1 (en) | 2018-12-14 | 2020-06-17 | DWI - Leibniz-Institut für Interaktive Materialien e.V. | Topical formulation in form of a patch, a bandage or a plaster comprising probiotic bacteria, and use thereof in a method for treating or preventing skin disorders |
WO2020120670A1 (en) | 2018-12-14 | 2020-06-18 | Dwi Leibniz-Institut Für Interaktive Materialien E.V. | Topical formulation in form of a patch, a bandage or a plaster comprising probiotic bacteria, and use thereof in a method for treating or preventing skin disorders |
WO2022185238A1 (en) * | 2021-03-04 | 2022-09-09 | Blis Technologies Limited | Topical composition and use thereof |
WO2024047589A1 (en) * | 2022-09-02 | 2024-03-07 | Blis Technologies Limited | Topical compositions of micrococcus luteus q24 and use thereof |
Also Published As
Publication number | Publication date |
---|---|
ES2430377T3 (en) | 2013-11-20 |
CN101163788B (en) | 2011-09-14 |
CA2602108C (en) | 2018-08-14 |
US20110189133A1 (en) | 2011-08-04 |
CA2602108A1 (en) | 2006-10-05 |
US8283136B2 (en) | 2012-10-09 |
DK1863899T3 (en) | 2013-10-14 |
CN101163788A (en) | 2008-04-16 |
EP1863899A4 (en) | 2009-12-30 |
AU2006229563B2 (en) | 2012-01-12 |
EP1863899A1 (en) | 2007-12-12 |
JP2008537549A (en) | 2008-09-18 |
NZ539076A (en) | 2008-05-30 |
EP1863899B1 (en) | 2013-07-10 |
JP5313659B2 (en) | 2013-10-09 |
PL1863899T3 (en) | 2014-01-31 |
AU2006229563A1 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2602108C (en) | Skin treatment compositions | |
JP6043325B2 (en) | Formulation of lactic acid bacteria and its use for the prevention and / or treatment of infectious diseases and inflammation | |
JP6267633B2 (en) | Novel lactic acid bacteria and composition containing the same | |
CA2833937C (en) | Lactobacillus strains, compositions containing them and use of the strains to prevent or treat conditions caused by streptococcus pyogenes | |
CN108697743B (en) | Composition of lactic bacteria for treating infections caused by propionibacterium acnes, in particular acne | |
KR101398347B1 (en) | Methods and means for protecting the skin against pathogenic microorganisms | |
US20210361978A1 (en) | Dermatological preparations for maintaining and/or restoring healthy skin microbiota | |
AU783418B2 (en) | Improved topical compositions containing probiotic bacteria, spores, and extracellular products and uses thereof | |
KR101925135B1 (en) | Novel strain of Cutibacterium avidum, and composition for preventing or treating atopic dermatitis comprising the strain or its culture fluid | |
AU2003206479B2 (en) | Antimicrobial composition | |
US20090035294A1 (en) | Lipopolysaccharide fractions of vitreoscilla filiformis useful for stimulating the synthesis of anti-microbial peptides of the skin | |
CN109890955A (en) | It is resistant to the lactic acid bacteria of antibacterial agent | |
KR20020068382A (en) | Agent which is anti-adhesive in relation to the pathogenic flora of the skin | |
KR102063554B1 (en) | Lactobacillus gasseri swpm102 which has antifungal activity or antibacterial activity | |
US20230218682A1 (en) | Topical Application of CRISPR-Modified Bacteria to Treat Acne Valgaris | |
WO2007052356A1 (en) | Antibacterial substance dm0507 and utilization of the same | |
PT2555785E (en) | Use of streptococcus salivarius in the treatment of chronic infections of the respiratory tract | |
EP3774855A1 (en) | <smallcaps/> p. acnes an antimicrobial composition for selectively inhibiting growth ofbacteria | |
KR102063544B1 (en) | Lactobacillus salivarius swpm101 which has antifungal activity or antibacterial activity | |
KR20200030715A (en) | A composition for preventing improving or treating bone disease comprising lactobacillus salivarius swpm101 and lactobacillus gasseri swpm102 | |
JP2022055482A (en) | Skin flora improver and topical skin preparation for improved skin flora | |
CN118541129A (en) | Skin care composition and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680010725.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006229563 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2602108 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008503984 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006733149 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006229563 Country of ref document: AU Date of ref document: 20060329 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006229563 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006733149 Country of ref document: EP |